课题基金 / 基金详情

项目摘要

项目成果

David A Tuveson的其他基金

相似基金

相关文献

中文摘要
翻译
总体-摘要
英文摘要
OVERALL – ABSTRACT The Cold Spring Harbor Laboratory (CSHL) Cancer Center is a preeminent institute for basic cancer research. More than 50 years ago, strategically focused efforts investigated the genetics of human cancer, laying the foundation for multiple breakthroughs today. As a result, researchers in the CSHL Cancer Center have made discoveries about how tumors initiate and progress, and they have produced novel tools, approaches, and cancer models that are used around the world. Over the last five years, the leadership of the CSHL Cancer Center transitioned smoothly, with David Tuveson assuming the role of Center Director. Tuveson substantially expanded the Cancer Center leadership team, reorganized the Programs and Shared Resources, and added new research infrastructure to support new initiatives and maintain the highly collaborative and integrated research in the Center. The CSHL Cancer Center now has 43 full members, who are divided into three research programs: Cancer Genetics and Genomics; Gene Regulation and Inheritance; and Cellular Communication in Cancer. The research in these Programs is supported by 10 Shared Resources, which provide access to cutting-edge technologies and expertise. This transition has propelled the Cancer Center’s research excellence. Broadly, the Cancer Center focuses on three major themes: defining the basic molecular mechanisms underpinning cancer development and progression; determining the features of neoplastic and stromal cellular heterogeneity that drive tumorigenesis; and developing novel experimental and computational technologies to assist cancer diagnosis and therapy. Center members published 408 cancer-relevant research papers during this funding cycle, with 41% in journals with an impact factor greater than 10. Cancer Center members were recognized for their significant contributions to science with 43 highly competitive national and international awards during this funding period. The Cancer Center continues to be highly collaborative, with 27% of publications representing a collaboration between at least two Center members. And finally, to support these efforts, members have obtained $11.8 million dollars in cancer-relevant, peer-reviewed funding. In the next funding period, the Cancer Center will continue to make foundational discoveries about cancer using basic research. At the same time, the Cancer Center is committed to increasing links to cancer patients and patient-derived models to facilitate an extension to human biology and clinical translation. Funds from the Cancer Center Support Grant will support the Cancer Center Leadership, Administration, Education and Training, the Developmental Funds that enhance innovative science, and the Shared Resources that provide essential technologies to advance our cancer research.
期刊论文(512)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1097/sla.0000000000004200
发表时间: 2020-09-01
期刊: Annals of surgery
影响因子: 9
作者: [Seppälä TT, Zimmerman JW, Sereni E, Plenker D, Suri R, Rozich N, Blair A, Thomas DL 2nd, Teinor J, Javed A, Patel H, Cameron JL, Burns WR, He J, Tuveson DA, Jaffee EM, Eshleman J, Szabolcs A, Ryan DP, Ting DT, Wolfgang CL, Burkhart RA]
通讯作者: Burkhart RA
PTP1B inhibitors protect against acute lung injury and regulate CXCR4 signaling in neutrophils.
PTP1B抑制剂可预防急性肺损伤并调节中性粒细胞中的CXCR4信号传导。
DOI: 10.1172/jci.insight.158199
发表时间: 2022-07-22
期刊: JCI INSIGHT
影响因子: 8
作者: [Song, Dongyan, Adrover, Jose M., Felice, Christy, Christensen, Lisa N., He, Xue-Yan, Merrill, Joseph R., Wilkinson, John E., Janowitz, Tobias, Lyons, Scott K., Egeblad, Mikala, Tonks, Nicholas K.]
通讯作者: Tonks, Nicholas K.
Shapeshifting bullvalene-linked vancomycin dimers as effective antibiotics against multidrug-resistant gram-positive bacteria.
塑造牛体连接的万古霉素二聚体作为抗多药耐药革兰氏阳性细菌的有效抗生素。
DOI: 10.1073/pnas.2208737120
发表时间: 2023-04-11
期刊: Proceedings of the National Academy of Sciences of the United States of America
影响因子: 11.1
作者: []
通讯作者:
Asterix/Gtsf1 links tRNAs and piRNA silencing of retrotransposons.
Asterix/Gtsf1 连接反转录转座子的 tRNA 和 piRNA 沉默。
DOI: 10.1016/j.celrep.2021.108914
发表时间: 2021-03-30
期刊: Cell reports
影响因子: 8.8
作者: [Ipsaro JJ, O'Brien PA, Bhattacharya S, Palmer AG 3rd, Joshua-Tor L]
通讯作者: Joshua-Tor L
共 302 条
    Fibroblast Heterogeneity in Pancreatic Cancer
    • 批准号:
      10675741
    • 项目类别:
    • 资助金额:
      $78.02万
    • 财政年份:
      2021
    • 负责人:
      David A Tuveson
    • 依托单位:
    Fibroblast Heterogeneity in Pancreatic Cancer
    • 批准号:
      10299050
    • 项目类别:
    • 资助金额:
      $81.89万
    • 财政年份:
      2021
    • 负责人:
      David A Tuveson
    • 依托单位:
    Fibroblast Heterogeneity in Pancreatic Cancer
    • 批准号:
      10467049
    • 项目类别:
    • 资助金额:
      $78.0万
    • 财政年份:
      2021
    • 负责人:
      David A Tuveson
    • 依托单位:
    Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response
    • 批准号:
      10056198
    • 项目类别:
    • 资助金额:
      $61.57万
    • 财政年份:
      2016
    • 负责人:
      David A Tuveson
    • 依托单位:
    海外基金